The cell culture medium developer has reeled in $14.9m from investors including strategic partner WuXi Biologics in its series A-plus round.

China-based based biotechnology developer Duoning Biotechnology has collected RMB100m ($14.9m) in a series A-plus round that included pharmaceutical company WuXi Biologics. The corporate took part through an undisclosed corporate venturing fund, investing alongside private equity firm Ally Bridge Group. It came after an undisclosed amount of series A funding from Shanghai Hongjia Asset Management Company…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.